Palvella TherapeuticsPVLA
Recorded

Palvella Therapeutics Stifel 2026 Healthcare Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Annabel SamimyAnalyst

Okay, I got it. All right. Good morning, everyone, and welcome to the Stifel Healthcare Conference. We are pleased to have Palvella with us, and Wes Kaupinen, who is the CEO of Palvella. Palvella, as you know, is developing the QTORIN or has a QTORIN platform in developing a number of programs in rare skin diseases and hopefully circling the wagons on, I think it was 600 rare skin diseases That is right.

Annabel SamimyAnalyst

in dermatology. Welcome. Wes, maybe you can just start with giving us an overview of the business, describe the company, the QTORIN platform, how capital efficient you are in terms of developing these programs, just to level set everyone.

Wes KaupinenCEO

Great. Well, thanks, Annabel. Great to be back with you here at the Stifel Conference for a second time. I will begin with the name Palvella. Palvella in Finnish means to serve, and so the mission of our company is to serve patients that have serious rare skin diseases and vascular anomalies which currently have no FDA-approved therapies. The vision for the company, Annabel alluded to it, is we want to build the enduring leader that is developing and commercializing therapies for patients suffering from serious rare skin diseases and vascular anomalies. Together, those two areas represent close to 700 diseases. Over 98% of those do not have a single approved treatment. This area is less competitive than other areas of orphan, like oncology and neurology. Our objective is to build the enduring leader in areas of high unmet need and low competitive intensity.

Wes KaupinenCEO

Our strategy can be summed up in a word, which is first. We are built to go from zero to one, take diseases that previously had nothing, and pioneer the first therapy for those patients and for those rare disease communities. The way that we are doing that is through, as Annabel alluded to, our QTORIN platform. This is a platform that allows us to reproducibly develop novel topical product candidates and then evaluate those product candidates in these rare skin diseases and vascular malformation where there is no approved treatments. There are three elements to QTORIN. That is our formulation expertise and topical formulation, it is our manufacturing know-how, and then applying a fit-for-purpose intellectual property strategy which allows us to generate long duration IP claims on each of our QTORIN product candidates. Capital efficiency, great to hear that capital efficiency is back in biotech. That really begins with a management philosophy.

Wes KaupinenCEO

Our philosophy at Palvella is to try to flush out as much risk on our programs on the smallest quantums of capital. We think that is the right approach to capital allocation. We have been that way since founding. We have recruited a senior leadership team, like Matt Korenberg, our CFO, our Chief Commercial Officer, Ashley Kline, Kathy Goin, our COO, Jeff Martini, our CSO, that shares that philosophy. Having an established platform in place certainly allows us to recognize capital efficiency as well. When we are bringing new programs into the platform because we have that existing formulation, manufacturing, and IP expertise, we believe we can go from concept to phase II data on much smaller quantums of capital compared to just starting programs de novo.

Annabel SamimyAnalyst

Great. What is exciting about Palvella right now is that your first NDA has been accepted, breakthrough designation, fast-tracked with a four-month review. Maybe you can tell us what you think that means for FDA willingness to accept unique trial designs for rare diseases, and how applicable do you think this is to other rare skin diseases that you are looking at?

Wes KaupinenCEO

Well, I think many of us in the rare disease space are really encouraged by this new framework that was recently announced by the FDA. I think there is a recognition by the new FDA leadership of the tremendous unmet need that still exists in rare disease. Our program, as you alluded to, we have been the beneficiary of multiple FDA designations, orphan designation, fast-track designation, which is designed to expedite therapies to patients. After our phase II data, we were granted breakthrough designation, and the FDA has also supported our MLM program with an FDA orphan product grant, which is non-dilutive capital that has been used to fund our phase III program and open-label extension study. Our most recent designations, we are following our pre-NDA meeting. We were granted rolling review of our NDA application, and just recently, at the end of October, we were granted FDA's priority review.

Wes KaupinenCEO

Because we are developing rapamycin, which is not a new molecular entity, there was a six-month priority review that was granted from the date of NDA submission. For us, that results in a PDUFA date on Rare Disease Day, which is February 28th of next year. We are all eyes forward at the company, focused on securing a timely approval, and we've made a strategic decision to really scale up our commercial and medical teams in advance of FDA approval such that we really want to have that commercial infrastructure in place several months ahead of the launch.

Annabel SamimyAnalyst

Yeah. Let's talk about those commercial preparations because they seem pretty extensive and expansive for the stage. Why don't you talk to us about the preparations that you've done here?

Wes KaupinenCEO

Sure. Thanks, Annabel. I'll begin with leadership. I think the success of the launch in a lot of ways is, yes, governed by the product profile, where we showed 95% of patients improving on the primary endpoint in phase III. We had 100% of patients improve on the clinical global impression of change in phase II. That's a foundational element of the launch success. But really, it's going to be the people who day-to-day are going to be working with physicians, working with payers, and in our case, working directly with patients through our patient access liaison team, that will ensure that this launch is very successful for the MLM community, and specifically those patients who are suffering from microcystic lymphatic malformations. On the leadership side, we hired Ashley Kline as our Chief Commercial Officer. She was able to be on her first earnings call just last week.

Wes KaupinenCEO

This is not Ashley's first orphan launch. She previously launched a drug called OXERVATE, which is a topical therapy for neurotrophic keratitis, previously a rare disease with no approved therapies. She brought that drug to market very successfully, and now does over $1 billion in sales annually. Ashley brings tremendous experience as a proven orphan commercial launch leader. We also have recruited others in our organization with rare disease experience, but also dermatology experience. One of the primary treaters of microcystic lymphatic malformations will be dermatologists, so we've been able to bring on Jen McDonough as our Head of Market Access and Reimbursement. Jen previously had a very similar role at Krystal Biotech, played a major role in their success launching VYJUVEK for patients with epidermolysis bullosa. Kent Taylor has been brought on as our Head of Sales.

Wes KaupinenCEO

Kent was previously at Arcutis, leading the sales organization there, helping to launch ZORYVE very successfully. We've also brought on the next layer of leadership on Kent's team, bringing on very strong area Vice Presidents as well as rare disease Directors. Our goal is to bring on the best of dermatology and rare disease experience, folks who are proven high performers, very entrepreneurial, and want to win for patients. One of the major thrusts we've been making with this new team that we have in place is have our team out in the field day in and day out, week in and week out, meeting with physicians, meeting with vascular anomaly centers. There's about 400 centers in the U.S. that have about half of this market, or 15,000 patients. Our goal is to be out meeting all of those centers prior to FDA approval next February.

Wes KaupinenCEO

We've met with over 200 of those centers to date, and we'll meet with more this week, and really pleased with the quality of the work that our team is doing.

Annabel SamimyAnalyst

Great. Ashley shared with us on the earnings call one of the surveys that you all had done to identify where the prescribers are. Can you talk a little bit about that, where they sit, how it's possibly changed your assumptions of either the market size, the treating population, and what can you share with us there?

Wes KaupinenCEO

Sure. New market research data that Ashley Kline presented last week, we did a survey of about 150 physicians in the U.S. Over 70% indicated that upon FDA approval, they would prescribe QTORIN rapamycin within three months of approval, and then over three-quarters indicated that they would prescribe QTORIN rapamycin for more than one microcystic lymphatic malformation patient. This is really encouraging market research data. I found that best practice is to always try to marry what you're seeing in third-party market research with what you're hearing in the field. Our medical affairs team and our commercial team, and being at medical congresses, and also being at the vascular anomaly centers, is hearing similar positive feedback. In terms of patient identification, this is a different sort of rare disease market than most that I've worked in over the last approximately 15 years.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day